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Background. Studies have shown that peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists could ameliorate renal ﬁ-
brotic lesions in both diabetic nephropathy and nondiabetic chronic kidney diseases. In order to elucidate the antiﬁbrotic mecha-
nism of PPAR-γ agonists, we investigated the eﬀects of PPAR-γ activation on TGF-β1-induced renal interstitial ﬁbroblasts. Meth-
ods. In rat renal interstitial ﬁbroblasts (NRK/49F), the mRNA expression of TGF-β1-induced α-smooth muscle actin (α-SMA),
connective tissue growth factor (CTGF), ﬁbronectin (FN) and collagen type III (Col III) were observed by reverse transcriptase-
polymerase chain reaction (RT-PCR). The protein expressions of FN and Smads were observed by Western blot. Results. In
NRK/49F, TGF-β1 enhanced CTGF, FN and Col III mRNA expression in a dose- and time-dependent manner. α-SMA, CTGF,
FN and Col III mRNA and FN protein expression in 15-deoxy-Δ
12,14-prostaglandin J2 (15d-PGJ2)-troglitazone- and ciglitazone-
pretreated groups, respectively, were signiﬁcantly decreased compared with the TGF-β1-stimulated group. TGF-β1( 5n g / m L )e n -
hanced p-Smad2/3 protein expression in a time-dependent manner. Compared with the TGF-β1-stimulated group, p-Smad2/3
protein induced by TGF-β1i nP P A R - γ agonists-pretreated groups signiﬁcantly decreased with no statistical diﬀerence amongst
the three pretreated groups. Conclusion. PPAR-γ agonists could inhibit TGF-β1-induced renal ﬁbroblast activation, CTGF expres-
sion and ECM synthesis through abrogating the TGF-β1/Smads signaling pathway.
Copyright © 2007 Weiming Wang et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Tubulointerstitial ﬁbrosis (TIF) is the ﬁnal manifestation of
end stage renal disease (ESRD) [1] and renal injury is corre-
latedtothedegreeofrenalinterstitialﬁbrosis.Oneofthema-
jor pathological characteristics of TIF is the activated tubu-
lointerstitial ﬁbroblasts transdiﬀerentiating into myoﬁbrob-
lasts. Furthermore, extracellular matrix (ECM) secreted by
ﬁbroblasts deposits in the tubular interstitium and results in
interstitial ﬁbrosis. Transforming growth factor-β (TGF-β)
is known to be one of the major mediators that lead to ﬁ-
brosis. Connective tissue growth factor (CTGF) has been re-
ceiving more and more attention for being one of the major
downstream mediators of TGF-β.P e r o x i s o m ep r o l i f e r a t o r -
activated receptor γ (PPAR-γ) is a member of the ligand-
activated nuclear transcriptional superfamily and is ex-
pressedinseveraltissueswhichincludeskidney[2–5].PPAR-
γ is activated by its ligand, 15-deoxy-Δ12,14-prostaglandin J2
(15d-PGJ2),oractivators(syntheticthiazolidinedionePPAR-
γ agonists) and then participates in the regulation of cel-
lular function [2]. Apart from maintaining glucose home-
ostasis, it also plays an important role in inﬂammation and
cell cycles. Studies have shown that PPAR-γ could control
glomerular inﬂammation, modulate vasodilator substances
likeprostaglandinsandNO[6,7],antagonizeglomeruloscle-
rosis of diabetic nephropathy, and improve renal function.
In a rat remnant kidney model of renal ﬁbrosis, administra-
tion of the PPAR-γ agonist troglitazone is associated with
reduction of proteinuria, improved serum creatinine, and
glomerulosclerosis [8]. PPAR-γ agonists could exert antiﬁ-
brotic eﬀects on human PTC in high glucose levels by atten-
uatingtheproductionofAP-1,TGF-β1,andthedownstream
production of the extracellular matrix protein ﬁbronectin
[8, 9]. PPAR-γ activation also decreases glomerular cell pro-
liferation and suppresses plasminogen activator inhibitor-1
(PAI-1) and TGF-β expression [10]. Furthermore, it down-
regulated TGF-β1-induced ﬁbronectin expression in mouse
glomerular mesangial cells by inhibiting activator protein-1
(AP-1) [11–13]; but the relationship between PPAR-γ and
tubulointerstitial ﬁbrosis is not clear yet. By studying the2 Mediators of Inﬂammation
eﬀects of PPAR-γ activation on TGF-β-induced ﬁbrosis and
its mechanism, our study demonstrates the potential per-
spective for the antiﬁbrotic property of PPAR-γ agonists.
2. MATERIALS AND METHODS
Cellcultureandtreatments
NRK-49F, the immortalized rat kidney interstitial ﬁbrob-
last cells were obtained from the Chinese Academy of
Sciences. Cells were maintained in DMEM/F-12 medium
supplemented with 10% heat-inactivated fetal calf serum
(Gibco/BRL) in a humidiﬁed atmosphere of 5% CO2/95%
air at 37◦C. The cells were passaged every 4 days and then
harvested onto six-well culture plates to 60–70% conﬂuence
in the complete medium for 16 hours followed by chang-
ing to serum-free medium. TGF-β1, 15d-PGJ2, troglitazone,
and ciglitazone (BIOMOL Research Laboratories, Inc., Ply-
mouth Meeting, Pa) were freshly dissolved in culture media
andaddedtotheculturesattheindicatedconcentrationsand
for the indicated time periods.
RNAisolationandReversetranscriptase-polymerase
chainreaction(RT-PCR)
Total RNA from NRK/49F cells was isolated by using a TRI-
zol extraction kit (Gibco/BRL) according to the manufac-
turer’s directions. First-strand cDNA was synthesized using
2μgo fR N Ai n2 0 μLo fr e a c t i o nb u ﬀer by reverse tran-
scription using Moloney murine leukemia virus-derived re-
verse transcriptase (Promega). Complementary DNA was
ampliﬁedin100μLtotalvolumewhichcontained50mmol/L
KCl,20mmol/LTris-HCl(pH8.0),10mmol/Ldeoxynucleo-
side triphosphate (dNTP), 1.5mmol/L MgCl2, 1U Taq poly-
merase,and10pmolofspeciﬁcPCRprimers.Table 1 showed
the sets of primers used for PCR ampliﬁcation. Beta-actin
was ampliﬁed and yielded a 202bp PCR product as the in-
ternal standard. The number of cycles used allowed quan-
tiﬁcation without saturation. Ampliﬁcation products were
separated by electrophoresis on 1.2% agarose gel, followed
by ethidium bromide staining, and then photographed. The
ampliﬁcation bands were quantitated from negative by scan-
ning densitometry. Semiquantitation was done by serial di-
lution of the input cDNA to measure the mRNA. The pro-
portion of speciﬁc gene product to β-actin product was used
for semiquantitive analysis.
Westernblotting
Extracted protein was loaded on a 10% SDS-PAGE gel
and transferred onto nitrocellulose membranes. Then pro-
teins were then blocked and incubated with speciﬁc anti-
bodies: β-actin (Sigma-Aldrich), ﬁbronectin (GIBco), type
III collagen (Sigma), Smad2/3, or p-smad2/3 (Santa Cruz
Biotechnology, Calif, USA). Membranes were subsequently
washed, incubated with speciﬁc secondary horseradish
peroxidase—conjugated antibodies, and revealed with the
enhanced chemiluminescence (ECL) kit (Life Science Prod-
ucts, Boston, Mass, USA). The band intensity was analyzed
by scanning densitometry.
Statisticalanalysis
All experiments were repeated at least three times, and the
results are presented as mean ± standard deviation (SD). All
data were analyzed by SAS 6.12. ANOVA and t-test were per-
formed for statistical analysis as appropriate. A P value less
than .05 was considered to be statistically signiﬁcant.
3. RESULTS
TGF-β1-inducedCTGF,FN,andColIIImRNAexpressionin
a dose-dependent and time-dependent manner in NRK/49F
cells.
The induction of CTGF and ECM expression is a hall-
mark of renal ﬁbrosis in many types of primary glomeru-
lar disease. Therefore, we ﬁrst examined the eﬀect of TGF-β1
on CTGF and ECM expression in cultured NRK/49F cells.
As shown in Figures 1 and 2, NRK/49F cells had basal ex-
pression of CTGF, FN, and Col III mRNA. After stimulat-
ing with diﬀerent concentration of TGF-β1, the expression
of CTGF, FN, and Col III mRNA increased signiﬁcantly in a
dose-dependent manner (see Figure 1). After stimulating at
1ng/mLTGF-β1for1hour,theexpressionofCTGF,FN,and
Col III mRNA began to increase (P<.05), peaked at 5ng/mL
(P<.01),anddecreasedat10ng/mLbutwasstillgreaterthan
that of the control group (P<.01). As shown in Figure 2,
TGF-β1 also induced CTGF, FN, Col III mRNA expression in
a time-dependent manner in NRK/49F cells. After stimulat-
ing for 6 hours with TGF-β1 (5ng/mL), expression of CTGF,
FN, and Col III mRNA increased, and peaked at 24 hours
(P<.01).
EffectsofPPAR-γ agonistsonα-SMA,CTGF,ColIII,andFN
mRNAexpression
The induction of α-SMA is a hallmark of renal intersti-
tial ﬁbroblast activation. Therefore, we examined the eﬀect
of PPAR-γ activation on α-SMA, CTGF, Col III, and FN
mRNA expression in cultured NRK/49F. As shown in Fig-
ures 3 and 4,1 0μM 15d-PGJ2 dramatically suppressed TGF-
β1-mediated α-SMA, CTGF, Col III, and FN mRNA ex-
pression (P<.05). Similarly, the synthetic PPAR-γ agonists
troglitazone, and ciglitazone also eﬀectively inhibited TGF-
β1-mediated α-SMA, CTGF, Col III, and FN mRNA expres-
sion in NRK/49F. Such expression in the troglitazone- and
ciglitazone-treated groups was less than that in the 15d-PGJ2
treated group.
EffectsofPPAR-γ agonistsonTGF-β-inducedFN
proteinexpression
Figure 5demonstratesthat15d-PGJ2,troglitazone,andcigli-
tazone suppressed TGF-β1-mediated ﬁbronectin expression
in NRK/49F cells. NRK/49F cells expressed a consider-
able amount of ﬁbronectin at basal conditions, and TGF-
β1 signiﬁcantly induced FN expression. However, NRK/49FWeiming Wang et al. 3
Table 1: PCR primer sequence and conditions.
Name Primer sequence Fragment length
α-SMA Upstream 5 -GATCACCATCGGGAATGAACGC-3 
388bp
Downstream 5 -CTTAGAAGCATTTGCGGTGGAC-3 
CTGF Upstream 5 -GAGCTTTCTGGCTGCACC-3 
250bp
Downstream 5 -TCTCCGTACATCTTCCTG-3 
FN Upstream 5 -TTATGACGATGGGAAGACCTA-3 
220bp
Downstream 5 -GTGGGGCTGGAAAGATTACTC-3 
Col III Upstream 5 -CTGGACCAAAAGGTGATGCTG-3 
560bp
Downstream 5 -TGCCAGGGAATCCTCGATGTC-3 
GAPDH Upstream 5 -GACAAGATGGTGAAGGTCGG-3 
505bp
Downstream 5 - CATGGACTGTGGTCATGAGC-3 
β-actin Upstream 5 - TGGAGAAGAGCTATGAGCTGCCTG-3 
202bp
Downstream 5 - GTGCCACCAGACAGCACTGTGTTG-3 
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Figure 1: TGF-β1-induced CTGF, FN, Col III mRNA expression in
a dose-dependent manner, ∗P<.05 versus control; #P<.01 versus
control (n = 3 for each group).
treatedwith15d-PGJ2,troglitazone,andciglitazonecounter-
acted the TGF-β1-stimulated overproduction of ﬁbronectin.
However, the level of ﬁbronectin in ﬁve PPAR-γ agonists
treated groups was not signiﬁcantly diﬀerent (P>.05).
EffectsofTGF-β1onSmadsproteinexpressioninNRK/49F
Figure 6 shows that NRK/49F had basal expression of phos-
phorylatedsmad2/3protein.AfterstimulatingbyTGF-β1for
15 minutes, p-Smad2/3 protein expression began to increase,
peaked at 1 hour, then began to decrease at 2 hours. There
was no diﬀerence of total Smad2/3 protein expression.
EffectsofPPAR-γ onTGF-β/Smadsproteinexpression
To explore the molecular mechanism by which PPAR-γ ag-
onists inhibit TGF-β1-mediated renal ﬁbroblast activation,
we studied the eﬀect of 15d-PGJ2, troglitazone, and cigli-
tazone on Smad signalling pathway. As shown in Figure 7,
pretreatment of NRK/49F ﬁbroblasts with 15d-PGJ2, trogli-
tazone, and ciglitazone was able to block Smad phospho-
rylation. There was no diﬀerence in each interfering group
(P>.05). Total Smad2/3 protein of each group showed no
diﬀerence.
4. DISCUSSION
Tubulointerstitial ﬁbrosis (TIF) is the ﬁnal manifestation
of end stage renal disease (ESRD). The major pathologi-
cal changes of TIF are the proliferation of interstitial ﬁ-
broblasts, transdiﬀerentiation of ﬁbroblast into myoﬁbrob-
lasts (the major characteristic of which is the increase of α-
smooth muscular actin expression), and overdepositing of
extracellular matrix (ECM) such as ﬁbronectin and colla-
gen type I, type II, and type IV. Of all the cytokines and
growth factors involved, TGF-β1 plays the most important
role. The elevation of TGF-β1 expression is closely correlated
with glomerulosclerosis and interstitial ﬁbrosis. Anti-TGF-
β1 antibody and anti-TGF-β receptor antibody could reduce
the production of ECM [14]. As TGF-β1h a sm a n yb i o l o g -
ical eﬀects, suppression of TGF-β1 expression/activation or
blocking TGF-β1 at its receptors could result in many bio-
logical side eﬀects. Therefore, targeting the downstream me-
diators of the over-activated signaling pathway is a good way
to antagonize the progression of ESRD and thus become the
prime focus of current studies.4 Mediators of Inﬂammation
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Figure 2: TGF-β1-induced CTGF, FN, Col III mRNA expression in
a time-dependent manner, ∗P<.05 versus control; eﬀects of TGF-
β1 on CTGF, FN, Col III mRNA expression in NRK/49F. NRK/49Fs
were cultured in the 25cm2 culture ﬂash by 1 × 106 which contains
DMEM/F12 medium with 10% fetal bovine serum, and cultured
in the 37◦C, 5%CO2 incubator. When the cells were 80–90% con-
ﬂuent, continued to culture in the DMEM/F12 medium without
serum for 24 hours to synchronize cell growth. Diﬀerent dosages
of TGF-β1 (0, 1, 2, 5, 10ng/mL) were added to the medium and
the cells were cultured for another 24 hours, or TGF-β1w a sa d d e d
(5ng/mL) to the medium and cultured for diﬀerent times (0, 6, 12
and 24 hours). Both control and experimental groups repeated for
3 times.
Connective tissue growth factor (CTGF) is one of the
downstream mediators of TGF-β1-induced ﬁbrosis and it
participates in ﬁbroblast proliferation and adhesion and in
inducing ECM production. Myoﬁbroblasts transdiﬀerenti-
ated from renal interstitial ﬁbroblasts are major sources of
tubulointerstitial ECM. Our study shows that NRK/49F had
basal expression of α-SMA mRNA until it is stimulated by
TGF-β1, whereupon its expression increased signiﬁcantly,
demonstrating that TGF-β1 could induce tubulointerstitial
ﬁbroblasts to transdiﬀerentiate into myoﬁbroblasts. TGF-β1
could increase the mRNA expression of the downstream
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Figure 3: Eﬀects of PPAR-γ agonists on TGF-β1-induced α-SMA,
FN, Col III mRNA expression. Cells were cultured as described
above and pretreated by 10uM 15d-PGJ2, troglitazone, and ciglita-
zone for 2 hours and then added 5ng/mL TGF-β1. Set a blank con-
trol group and 5ng/mL TGF-β1 stimulating group, cultured for 24
hours and then harvested the cells. Both control and experimental
groupsrepeatedfor3times.(1)control,(2)5ng/mLT GF -β1group,
(3) 15d-PGJ2 + 5ng/mL TGF-β1 group, (4) troglitazone + 5ng/mL
TGF-β1 group, (5) ciglitazone + 5ng/mL TGF-β1 group, ∗P<.05
versus control, #P<.05 versus 5ng/mL TGF-β1 group,  P<.05
versus 15d-PGJ2 group.
mediator CTGF and major constituents of ECM (collagen
type III and ﬁbronectin) in a time-dependent and dose-
dependent manner. Our study demonstrates that TGF-β is
oneofthemajorﬁbrosis-inducingmediatorswhichcouldin-
duce transdiﬀerentiation of renal ﬁbroblasts and production
of ECM. Recently, study by Lin et al. showed that activation
of Smad3/4 was essential for TGF-β1–induced CTGF tran-
scription and that pentoxifylline (PTX), a potent inhibitor
of CTGF, could inhibit CTGF expression by interfering with
Smad3/4-dependentCTGFtranscriptionthroughproteinki-
nase A and block the proﬁbrogenic eﬀects of CTGF on renal
cells [28].
PPAR-γ has now become the therapeutic target of
research on kidney diseases like diabetic nephropathy,
glomerulosclerosis, glomerulonephritis, and hypertensiveWeiming Wang et al. 5
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Figure 4: Eﬀects of PPAR-γ agonists on TGF-β1-induced CTGF
mRNA expression (n = 3 for each group), (1) control, (2) 5ng/mL
TGF-β1group,(3)15d-PGJ2+5ng/mLTGF-β1group,(4)troglita-
zone + 5ng/mL TGF-β1 group, and (5) ciglitazone + 5ng/mL TGF-
β1 group, P<.05 versus control, #P<.05 versus 5ng/mL TGF-β1
group,  P<. 0 5v e r s u s1 5 d - P G J 2g r o u p .
1234 56
FN
Actin
Figure 5: Eﬀects of PPAR-γ on TGF-β1-induced FN protein ex-
pression. Cells were cultured in the methods described above. Set
groups: (1) control group (without TGF-β1), (2) added 2ng/mL
TGF-β1; (3) 5ng/mL TGF-β1 group; (4) 10uM 15d-PGJ2 +
5ng/mLTGF-β1 group; (5) 10uM Troglitazone + 5ng/mL TGF-β1
group;(6)10uMciglitazone+5ng/mLTGF-β1group(allthethree
reagents were pretreated for 2 hours). All the cells in each group
were cultured for 24 hours and then harvested cells, extracted total
protein (results of one of the three repeated experiments).
nephropathy [2]. 15d-PGJ2 is the natural ligand of PPAR-
γ, and thiazolidinediones (TZDs) such as troglitazone, and
rosiglitazone are its agonists. It has been proven in animal
models (streptozotocin-induced diabetic nephropathy mod-
els and 5/6 nephrectomized models) that TZDs could reduce
the expression of extraglomerular matrix and ameliorate re-
nal injury [2]. TZDs and 15d-PGJ2 could reduce production
of collagen type I and ﬁbronectin in rats [15, 16], and inhibit
production of proinﬂammatory cytokines and chemotactic
factors (e.g., NO, COX-2, MCP-1, etc.) [17, 18]. Tubuloint-
erstitial ﬁbroblasts could express basal amounts of PPAR-γ.
Our unpublished study showed that PPAR-γ could inhibit
proliferationofhumantubulointerstitialﬁbroblastsandtrig-
ger their apoptosis. However, there are few studies on PPAR-
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Figure 6: Eﬀects of TGF-β1 on Smad2/3, p-smad2/3 protein ex-
pressioninNRK/49F(resultsofoneofthreerepeatedexperiments).
γ agonists and production of ECM. Our study found that
15d-PGJ2, troglitazone, and rosiglitazone could reduce TGF-
β-induced production of α-SMA and ECM (collagen type
III and ﬁbronectin) and inhibit expression of CTGF mRNA.
These results show that PPAR-γ agonists have an antiﬁbrotic
eﬀect through inhibition of TGF-β-induced renal ﬁbroblast
transdiﬀerentiation and ECM production. Such results are
similar to those results of studies on glomerulosclerosis and
arteriosclerosis [19–21]. Exposure of human cortical ﬁbrob-
lasts to pioglitazone causes an antiproliferative eﬀect and re-
ducesECMproductionthroughmechanismsthatincludere-
ducing TIMP activity independent of TGF-β1[ 22].
Diﬀerent PPAR-γ ligands or agonists may have diﬀerent
mechanisms in diﬀerent cells and there are also PPAR-γ in-
dependent pathways involved. Baoling found that pioglita-
zone, and 15d-PGJ2 could inhibit expression of ﬁbronectin
induced by TGF-β in rats and the eﬀects of pioglitazone are
due to activation of PPAR-γ. However, there were PPAR-γ-
independent pathways involved in the mechanism of 15d-
PGJ2action[16].WhetherPPAR-γ inhibitsTGF-β1-induced
ﬁbrosis by activating intracellular PPAR-γ-receptors requires
further study. Diﬀerent PPAR-γ agonists may even have op-
posite eﬀects. Sawano’s study shows that 15d-PGJ2 could
downregulateIL-1β-inducedCOX-2expressionandtroglita-
zone/rosiglitazonecouldnotreducetheexpressionofCOX-2
[17]. Panzer found that in experimental glomerulonephri-
tis induced by ATS (antithymus antibody), troglitazone, and
ciglitazone could upregulate MCP-1 expression and increase
monocyte/macrophage inﬁltration and adhesion, however,
15d-PGJ2hasnoeﬀectonMCP-1expression[23].Ourstudy6 Mediators of Inﬂammation
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Figure 7: Eﬀects of PPAR-γ on TGF-β1-induced Smads protein ex-
pression (results of one of the three repeated experiments): (1) con-
trol, (2) 2ng/mL TGF-β1g r o u p ,( 3 )5n g / m LT G F - β1g r o u p ,( 4 )
15d-PGJ2 + 5ng/mL TGF-β1 group, (5) troglitazone + 5ng/mL
TGF-β1 group, (6) ciglitazone + 5ng/mL TGF-β1 group,
shows that troglitazone, and ciglitazone have a more in-
hibitory eﬀect on α-SMA expression than 15d-PGJ2. Com-
paring the intervention of diﬀerent reagents, the expression
of CTGF, collagen type III, and ﬁbronectin shows no diﬀer-
ence. Such results suggest that these reagents have similar ef-
fects on ﬁbrosis.
Phosphorylated Smad2/Smad3 (p-Smad2/3) is the main
signaling pathway of TGF-β1 and it participates in the bio-
logical eﬀects of TGF-β which include cell proliferation, in-
ﬂammation reaction, and ﬁbrosis [24, 25]. They are essen-
tial mediators of TGF-β-induced endothelial cell transdif-
ferentiation and ECM and CTGF expression [26]. Studies
haveshownthattheTGF-β/Smadssignalingpathwaypartici-
pates in many pathophysiological processes related to kidney
diseases like diabetic nephropathy, glomerulonephritis and
glomerulosclerosis [27]. Our study shows that TGF-β1 in-
duces Smad2/3 phosphorylation in a time-dependent man-
ner, which suggests that TGF-β could induce Smad2/3 phos-
phorylation in renal ﬁbroblasts. 15d-PGJ2, troglitazone, and
ciglitazone could reduce TGF-β-induced p-Smad2/3 protein
expression while the total amount of Smad2/3 protein did
not change. Such results suggest PPAR-γ agonists could in-
hibit the ﬁbrotic eﬀect of TGF-β by interfering in the phos-
phorylation of Smad2/3. Moreover, all three reagents show
no signiﬁcant diﬀerence in inhibiting phosphorylation of
Smad2/3. Our study suggests that Smad 2/3 signaling path-
way is essential in antiﬁbrotic eﬀects of PPAR-γ agonists.
While in the study by Yang et al., Smad 2/3 phosphorylation
was not inhibited by hepatocyte growth factor (HGF), which
acts as a potent inhibitor of the TGF-β1-mediated myoﬁ-
broblasticactivation[29] Therefore,furtherstudyis required
to investigate role of Smad signaling pathway in diﬀerent in-
hibitors of TGF-β1-mediated myoﬁbroblastic activation.
In conclusion, PPAR-γ could antagonize TGF-β-induced
ﬁbrosis by interfering TGF-β/Smad signaling pathway. Such
results suggest a perspective for the antiﬁbrotic eﬀects of
PPAR-γ and such eﬀects may become the therapeutic target
of ESRD.
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